Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit.
The participant has a history of migraine onset ≥ 12 months prior to the Screening Visit.
The participant has a migraine onset at ≤50 years of age.
The participant has ≥4 migraine days per month for each month within the past 3 months prior to the Screening Visit.
The participant has documented evidence of treatment failure in the past 10 years of at least 1 to 4 (maximum) different migraine preventive medications.
You may not be if
The participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (anti-PACAP treatment).
The participant has confounding and clinically significant pain syndromes.
The participant has a diagnosis of acute or active temporomandibular disorder.
The participant has a history or diagnosis of confounding headaches.
Additional protocol-defined criteria apply.
Clareo Health | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
